CZ280879B6 - Použití účinné látky flupirtinu pro odstranení svalového přepětí - Google Patents

Použití účinné látky flupirtinu pro odstranení svalového přepětí Download PDF

Info

Publication number
CZ280879B6
CZ280879B6 CS912101A CS210191A CZ280879B6 CZ 280879 B6 CZ280879 B6 CZ 280879B6 CS 912101 A CS912101 A CS 912101A CS 210191 A CS210191 A CS 210191A CZ 280879 B6 CZ280879 B6 CZ 280879B6
Authority
CZ
Czechia
Prior art keywords
flupirtine
muscle
acid
medicament
flupirtin
Prior art date
Application number
CS912101A
Other languages
Czech (cs)
English (en)
Inventor
Michael Dr. Lobisch
Venhaus Dr. Ralph
Bernd Dr. Nickel
Istvan Prof. Szelenyi
Jürgen Prof. Engel
Peter Dr. Emig
Original Assignee
Asta Medica Aktiengesellschaft
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Asta Medica Aktiengesellschaft filed Critical Asta Medica Aktiengesellschaft
Publication of CS210191A3 publication Critical patent/CS210191A3/cs
Publication of CZ280879B6 publication Critical patent/CZ280879B6/cs

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445—Non condensed piperidines, e.g. piperocaine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A61P21/02—Muscle relaxants, e.g. for tetanus or cramps
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs

Landscapes

  • Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Epidemiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Neurology (AREA)
  • Engineering & Computer Science (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Neurosurgery (AREA)
  • Biomedical Technology (AREA)
  • Psychology (AREA)
  • Pain & Pain Management (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Agricultural Chemicals And Associated Chemicals (AREA)
  • Pyrrole Compounds (AREA)
  • Details Of Television Scanning (AREA)
  • Paints Or Removers (AREA)
  • Golf Clubs (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Oxygen Or Sulfur (AREA)
  • Medicines Containing Plant Substances (AREA)
CS912101A 1990-07-14 1991-07-08 Použití účinné látky flupirtinu pro odstranení svalového přepětí CZ280879B6 (cs)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
DE4022442 1990-07-14
IN421CA1991 IN172468B (enEXAMPLES) 1990-07-14 1991-06-04

Publications (2)

Publication Number Publication Date
CS210191A3 CS210191A3 (en) 1992-02-19
CZ280879B6 true CZ280879B6 (cs) 1996-04-17

Family

ID=25895002

Family Applications (1)

Application Number Title Priority Date Filing Date
CS912101A CZ280879B6 (cs) 1990-07-14 1991-07-08 Použití účinné látky flupirtinu pro odstranení svalového přepětí

Country Status (30)

Country Link
US (2) US5162346A (enEXAMPLES)
EP (2) EP0467164B1 (enEXAMPLES)
KR (1) KR0182811B1 (enEXAMPLES)
CN (1) CN1070700C (enEXAMPLES)
AT (2) ATE206919T1 (enEXAMPLES)
AU (1) AU634073B2 (enEXAMPLES)
CA (1) CA2046943C (enEXAMPLES)
CZ (1) CZ280879B6 (enEXAMPLES)
DE (3) DE59109222D1 (enEXAMPLES)
DK (2) DK0659410T3 (enEXAMPLES)
EG (1) EG19814A (enEXAMPLES)
ES (2) ES2082887T3 (enEXAMPLES)
GR (1) GR3019179T3 (enEXAMPLES)
HR (1) HRP920667B1 (enEXAMPLES)
HU (1) HU206973B (enEXAMPLES)
IE (1) IE74688B1 (enEXAMPLES)
IL (1) IL98810A (enEXAMPLES)
IN (1) IN172468B (enEXAMPLES)
LT (1) LT3593B (enEXAMPLES)
LV (1) LV10048B (enEXAMPLES)
MC (1) MC2272A1 (enEXAMPLES)
MX (1) MX9100160A (enEXAMPLES)
NO (1) NO912758L (enEXAMPLES)
NZ (1) NZ238940A (enEXAMPLES)
PT (1) PT98291B (enEXAMPLES)
RO (1) RO108220B1 (enEXAMPLES)
RU (1) RU2070408C1 (enEXAMPLES)
SI (1) SI9111227B (enEXAMPLES)
SK (1) SK279567B6 (enEXAMPLES)
ZA (1) ZA915466B (enEXAMPLES)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CZ298115B6 (cs) * 1995-11-07 2007-06-27 Meda Pharma Gmbh & Co. Kg Flupirtin nebo jeho farmaceuticky prijatelné solik príprave léciv k osetrování nemocí souvisejících s poskozováním hematopoetického bunecného systému

Families Citing this family (38)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ES2111659T3 (es) * 1992-03-11 1998-03-16 Asta Medica Ag Comprimidos, granulados y nodulos con alto contenido en sustancias activas para formas de administracion solidas de alta concentracion.
DE4319649A1 (de) * 1993-03-18 1994-09-22 Asta Medica Ag Feste Flupirtin enthaltende orale Darreichungsformen mit kontrollierter Wirkstoffabgabe
DE4327516A1 (de) * 1993-08-17 1995-02-23 Asta Medica Ag Primäre und sekundäre neuroprotektive Wirkung bei neurodegenerativen Erkrankungen von Flupirtin
GB9426079D0 (en) * 1994-12-23 1995-02-22 Orion Yhtymae Oy A gelatine capsule
US6284794B1 (en) 1996-11-05 2001-09-04 Head Explorer Aps Method for treating tension-type headache with inhibitors of nitric oxide and nitric oxide synthase
US6610324B2 (en) * 1999-04-07 2003-08-26 The Mclean Hospital Corporation Flupirtine in the treatment of fibromyalgia and related conditions
SK1712002A3 (en) * 1999-08-03 2003-03-04 Awd Pharma Gmbh & Co Kg Use of flupirtine for alleviating pain caused by degenerative joint diseases in dogs and cats
US6821995B1 (en) 1999-12-01 2004-11-23 Duke University Method of treating batten disease
US20040122090A1 (en) * 2001-12-07 2004-06-24 Lipton Stuart A. Methods for treating neuropsychiatric disorders with nmda receptor antagonists
RU2213565C1 (ru) * 2002-06-24 2003-10-10 Общество с ограниченной ответственностью "Паркинфарм" Способ лечебного воздействия на организм пациента при лечении болезни паркинсона
DE10255415A1 (de) * 2002-11-28 2004-06-09 Bayer Healthcare Ag Dermale Applikation von Flupirtin
DE10327674A1 (de) * 2003-06-20 2005-01-05 Awd.Pharma Gmbh & Co. Kg Injizierbare Darreichungsform von Flupirtin
US7799832B2 (en) * 2003-10-23 2010-09-21 Valeant Pharmaceuticals North America Combinations of retigabine and sodium channel inhibitors or sodium channel-influencing active compounds for treating pains
DE102004001558A1 (de) * 2004-01-10 2005-08-18 Bayer Healthcare Ag Arzneimittel zur topischen Applikation bei Tieren
US20050196461A1 (en) * 2004-01-14 2005-09-08 Udell Ronald G. Ceramide formulations suitable for oral administration
KR20060124731A (ko) * 2004-01-29 2006-12-05 뉴로몰레큘라 파마슈티칼스, 인코포레이티드 중추신경계-관련 질환 치료용 ｎｍｄａ 수용체 길항제 및ｍａｏ-억제제 또는 ｇａｄｐｈ-억제제의 배합물
US20050220862A1 (en) 2004-03-31 2005-10-06 Bernstein Joel E Compositions with reduced hepatotoxicity
US7619007B2 (en) * 2004-11-23 2009-11-17 Adamas Pharmaceuticals, Inc. Method and composition for administering an NMDA receptor antagonist to a subject
EP1688141A1 (en) * 2005-01-31 2006-08-09 elbion AG The use of flupirtine for the treatment of overactive bladder and associated diseases, and for the treatment of irritable bowel syndrome
PL1874282T3 (pl) 2005-04-06 2011-04-29 Adamas Pharmaceuticals Inc Sposoby i kompozycje do leczenia zaburzeń OUN
CA2650853A1 (en) * 2006-05-02 2007-11-15 Chris Rundfeldt Potassium channel activators for the prevention and treatment of dystonia and dystonia-like symptoms
US7960436B2 (en) * 2006-06-05 2011-06-14 Valeant Pharmaceuticals International Substituted arylamino-1,2,3,4-tetrahydro naphthalenes and-2,3-dihydro-1H-indenes as potassium channel modulators
JP5419691B2 (ja) * 2006-08-23 2014-02-19 バレアント ファーマシューティカルズ インターナショナル カリウムチャネルモジュレーターとしての４−（ｎ−アザシクロアルキル）アニリドの誘導体
US8993593B2 (en) * 2006-08-23 2015-03-31 Valeant Pharmaceuticals International N-(4-(6-fluoro-3,4-dihydroisoquinolin-2(1H)-yl)-2,6-dimethylphenyl)-3,3-dimethylbutanamide as potassium channel modulators
US8722929B2 (en) * 2006-10-10 2014-05-13 Valeant Pharmaceuticals International N-[2-amino-4-(phenylmethoxy)phenyl] amides and related compounds as potassium channel modulators
AU2007325629A1 (en) * 2006-11-28 2008-06-05 Valeant Pharmaceuticals International 1,4 diamino bicyclic retigabine analogues as potassium channel modulators
US20080279930A1 (en) * 2007-05-07 2008-11-13 Bernd Terhaag Controlled-Release Flupirtine Compositions, Compacts, Kits and Methods of Making and Use Thereof
US8367684B2 (en) * 2007-06-13 2013-02-05 Valeant Pharmaceuticals International Derivatives of 4-(N-azacycloalkyl) anilides as potassium channel modulators
US8563566B2 (en) * 2007-08-01 2013-10-22 Valeant Pharmaceuticals International Naphthyridine derivatives as potassium channel modulators
JP2011513196A (ja) * 2007-08-01 2011-04-28 ハー・ルンドベック・アクチエゼルスカベット ドーパミン作動系が破壊された障害もしくは状態の症状を軽減するためまたはその障害もしくは状態を処置するためのｋｃｎｑカリウムチャネル開口薬の使用
US7786146B2 (en) * 2007-08-13 2010-08-31 Valeant Pharmaceuticals International Derivatives of 5-amino-4,6-disubstituted indole and 5-amino-4,6-disubstituted indoline as potassium channel modulators
ES2347119B2 (es) * 2009-04-22 2011-04-28 Universidad De Santiago De Compostela Nanocapsulas de poliarginina.
DE102010030053A1 (de) 2010-06-14 2011-12-15 Awd.Pharma Gmbh & Co.Kg Injizierbare Darreichungsform von Flupirtin
JP6251667B2 (ja) * 2014-06-03 2017-12-20 アサヒカルピスウェルネス株式会社 錠剤型即放性製剤及びその製造方法
DE102017007385A1 (de) 2017-08-02 2019-02-07 Christoph Hoock Maleatfreie feste Arzneimittelformen
TWI886158B (zh) 2019-10-10 2025-06-11 加拿大商再諾製藥公司 選擇性鉀通道調節劑之固態晶型
NZ787838A (en) 2019-11-08 2025-08-29 Xenon Pharmaceuticals Inc Methods of treating depressive disorders
CA3207191A1 (en) 2021-02-09 2022-08-18 Simon Neil PIMSTONE Voltage-gated potassium channel opener for use in treating anhedonia

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE1795858C2 (de) 1968-07-19 1979-01-11 Deutsche Gold- Und Silber-Scheideanstalt Vormals Roessler, 6000 Frankfurt Benzylaminopyridine
DE3133519A1 (de) 1980-09-13 1982-06-09 Degussa Ag, 6000 Frankfurt "2-amino-3-carbethoxyamino-6-(p-fluor-benzylamino)-pyridin-maleat"
DE3665538D1 (en) * 1985-01-23 1989-10-19 Asta Pharma Ag Synergistic combination of flupirtin and non-steroidal anti-phlogistics
EP0193056B1 (de) * 1985-02-23 1989-06-07 ASTA Pharma Aktiengesellschaft Kombination von Flupirtin und anticholinergisch wirkenden Spasmolytika
DE3604575A1 (de) 1985-02-23 1986-08-28 Degussa Ag, 6000 Frankfurt Kombination von flupirtin und anticholinergisch wirkenden spasmolytika
FI855016A7 (fi) * 1985-06-28 1986-12-29 Degussa Flupirtiinin ja 4-asetamido-fenolin synergistinen yhdistelmä.

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CZ298115B6 (cs) * 1995-11-07 2007-06-27 Meda Pharma Gmbh & Co. Kg Flupirtin nebo jeho farmaceuticky prijatelné solik príprave léciv k osetrování nemocí souvisejících s poskozováním hematopoetického bunecného systému

Also Published As

Publication number Publication date
LT3593B (en) 1995-12-27
EP0659410B1 (de) 2001-10-17
EP0467164A3 (en) 1992-04-15
IE74688B1 (en) 1997-07-30
PT98291B (pt) 1999-01-29
KR0182811B1 (ko) 1999-05-01
HRP920667A2 (en) 1996-10-31
LTIP919A (en) 1995-03-27
EP0467164B1 (de) 1996-01-31
DE4122166A1 (de) 1992-01-16
EP0467164A2 (de) 1992-01-22
ES2164111T3 (es) 2002-02-16
ES2082887T3 (es) 1996-04-01
LV10048A (lv) 1994-05-10
RO108220B1 (ro) 1994-03-31
MX9100160A (es) 1992-02-28
EP0659410A3 (de) 1995-10-25
ATE133564T1 (de) 1996-02-15
HRP920667B1 (en) 1998-06-30
NZ238940A (en) 1997-05-26
US5162346A (en) 1992-11-10
IE912451A1 (en) 1992-01-15
HU912359D0 (en) 1991-12-30
HU206973B (en) 1993-03-01
GR3019179T3 (en) 1996-06-30
AU634073B2 (en) 1993-02-11
AU8040391A (en) 1992-01-16
CN1058716A (zh) 1992-02-19
CA2046943C (en) 1996-03-12
ATE206919T1 (de) 2001-11-15
MC2272A1 (fr) 1993-06-23
EG19814A (en) 1996-02-29
SI9111227A (en) 1995-06-30
US5284861A (en) 1994-02-08
DE59109222D1 (de) 2001-11-22
EP0659410A2 (de) 1995-06-28
CN1070700C (zh) 2001-09-12
SI9111227B (sl) 2000-12-31
PT98291A (pt) 1992-05-29
CA2046943A1 (en) 1992-01-15
SK279567B6 (sk) 1999-01-11
DK0659410T3 (da) 2001-12-27
CS210191A3 (en) 1992-02-19
RU2070408C1 (ru) 1996-12-20
NO912758L (no) 1992-01-15
LV10048B (en) 1995-06-20
IL98810A0 (en) 1992-07-15
DK0467164T3 (da) 1996-03-04
IL98810A (en) 1996-01-19
IN172468B (enEXAMPLES) 1993-08-14
HUT59313A (en) 1992-05-28
ZA915466B (en) 1992-04-29
DE59107331D1 (de) 1996-03-14
KR920002147A (ko) 1992-02-28
NO912758D0 (no) 1991-07-12

Similar Documents

Publication Publication Date Title
CZ280879B6 (cs) Použití účinné látky flupirtinu pro odstranení svalového přepětí
CA2009593C (en) Medicament containing dihydrolipoic acid as active substance
US4812481A (en) Synergistic combination of amantadiene and selegiline
EP0378086B1 (de) Verwendung des Wirkstoffs Azelastin zur Bekämpfung von Psoriasis-Erkrankungen
US4668684A (en) Combination of flupirtin and anticholinergic acting spasmolytic
DE69427551T2 (de) Nalbuphinester und diese enthaltende Arzneimittel mit verzögerter Wirkstoffabgabe
DD267187A5 (de) Verfahren zur herstellung von mitteln zur bekaempfung des asthma bronchiale und der chonisch obstruktiven bronchitis
JPH05509293A (ja) 不整脈および発作の治療における５―ｈｔ４受容体拮抗剤の使用
CA2684174C (fr) Utilisation du 4-cyclopropylmethoxy-n-(3,5-dichloro-1-oxydo-pyridin-4-yl)-5-(methoxy)pyridine-2-carboxamide pour le traitement des desordres moteurs lies a la maladie de parkinson
JPH0529208B2 (enEXAMPLES)
EP0492747B1 (en) Pharmaceutical preparation for topical application
CA1328613C (en) Hypotensive agent comprising 4' ethyl-2-methyl-3-piperidinopropiophenone
JPH0532627A (ja) 筋肉痙攣により帰因するか又は筋肉痙攣の結果である疾病及び症候群を治療するための医薬品及びその製法
JP3141051B2 (ja) 抗動脈硬化剤
FR2649322A1 (fr) Complexes biodisponibles d'acide (alpha)-linolenique, extraits de plantes en contenant et compositions pharmaceutiques les incorporant
JPH0448776B2 (enEXAMPLES)
IE84029B1 (en) Use of the compound flupirtin for the preparation of a medicament against muscle bracing
JPS61204124A (ja) 冠血管拡張剤
JPS63135370A (ja) 抗アレルギ−剤
Dave Formulation, Optimization and Evaluation of Medicated Chewing Gum for Combination
JP2011052023A (ja) イブプロフェン含有経口用組成物

Legal Events

Date Code Title Description
IF00 In force as of 2000-06-30 in czech republic
MK4A Patent expired

Effective date: 20110708